Prostate cancer–associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

(2016) Peter A. Humphrey et al.   EUROPEAN UROLOGY

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

(2016) Shaokun Shu et al.   NATURE

Organoid culture systems for prostate epithelial and cancer tissue

(2016) Jarno Drost et al.   Nature Protocols

Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity

(2016) Qing Zhong et al.   Scientific Reports

The Molecular Taxonomy of Primary Prostate Cancer

(2015) Adam Abeshouse et al.   CELL

SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression

(2015) Wenjian Gan et al.   MOLECULAR CELL

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

(2015) Philipp Rathert et al.   NATURE

BET inhibitor resistance emerges from leukaemia stem cells

(2015) Chun Yew Fong et al.   NATURE

Phthalimide conjugation as a strategy for in vivo target protein degradation

(2015) G. E. Winter et al.   SCIENCE

Organoid Cultures Derived from Patients with Advanced Prostate Cancer

(2014) Dong Gao et al.   CELL

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

(2014) Irfan A. Asangani et al.   NATURE

Targeting bromodomains: epigenetic readers of lysine acetylation

(2014) Panagis Filippakopoulos et al.   NATURE REVIEWS DRUG DISCOVERY

Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer

(2014) J.-P. P. Theurillat et al.   SCIENCE

Drug Resistance in Cancer: An Overview

(2014) Genevieve Housman et al.   Cancers

The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications

(2013) Pascal Genschik et al.   EMBO JOURNAL

Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting

(2013) Shwu-Yuan Wu et al.   MOLECULAR CELL

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

The bromodomain interaction module

(2012) Panagis Filippakopoulos et al.   FEBS LETTERS

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

(2012) Christopher E Barbieri et al.   NATURE GENETICS

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Common Gene Rearrangements in Prostate Cancer

(2011) Mark A. Rubin et al.   JOURNAL OF CLINICAL ONCOLOGY

COP1 is a tumour suppressor that causes degradation of ETS transcription factors

(2011) Alberto C. Vitari et al.   NATURE

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phosphorylation by Casein Kinase I Promotes the Turnover of the Mdm2 Oncoprotein via the SCFβ-TRCP Ubiquitin Ligase

(2010) Hiroyuki Inuzuka et al.   CANCER CELL

Suppression of inflammation by a synthetic histone mimic

(2010) Edwige Nicodeme et al.   NATURE

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Structures of SPOP-Substrate Complexes: Insights into Molecular Architectures of BTB-Cul3 Ubiquitin Ligases

(2009) Min Zhuang et al.   MOLECULAR CELL

Bromodomain 4 activation predicts breast cancer survival

(2008) N. P. S. Crawford et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA